KEN SHE Study
Phase 4
- Conditions
- Cancer
- Registration Number
- PACTR202002647375231
- Lead Sponsor
- niversity of Wshington
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other
- Sex
- Female
- Target Recruitment
- 2275
Inclusion Criteria
•Born female
•Age 15 to 20 years
•Sexually active: history of 1-5 lifetime partners
•Resident within study area without plans to move away in the next 37 months
Exclusion Criteria
•HIV positive rapid result
•History of HPV vaccination
•Allergies to vaccine components or latex,
•Pregnancy
•Hysterectomy
•Autoimmune, degenerative, and genetic diseases
•Investigator discretion
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the efficacy of single-dose HPV vaccination compared to multi-dose regimens in preventing cervical cancer in Kenya?
How does the single-dose HPV vaccine in PACTR202002647375231 induce immune responses against high-risk HPV subtypes like 16 and 18?
What biomarkers correlate with long-term protection from HPV-related cancers following single-dose vaccination in sub-Saharan African populations?
Are there adverse event profiles associated with single-dose HPV vaccines that differ from standard multi-dose protocols in adolescent females?
How does the University of Washington's single-dose HPV strategy compare to GSK/MSD's multi-dose vaccines in low-resource settings?